从皮损类型、血清标志物和影像学特征评估皮肌炎合并肺间质病变

doi:10.35541/cjd.20220388

Abstract

Abstract: 【Abstract】 Dermatomyositis is an autoimmune disease mainly involving the skin and muscles, as well as the heart, lungs, and joints, and it may even be complicated by malignant tumors. Among these complications, interstitial lung disease （ILD） is of particular concern. Because of the urgent onset and rapid progress, ILD is hard to diagnose at the early stage, leading to treatment delay. Furthermore, ILD is the common cause of death in patients with dermatomyositis. This review summarizes types of skin lesions, serum biomarkers and radiological features to evaluate the risk, severity and prognosis of dermatomyositis complicated by ILD.

Key words: Dermatomyositis, Lung disease, interstitial, Skin lesion, Biomarker, Radiological technology

Ye Jiaqi, Chai Weimin, Zheng Jie, Cao Hua. Evaluation of dermatomyositis complicated by interstitial lung disease based on skin lesions, serum biomarkers and radiological features[J]. Chinese Journal of Dermatology,2023,e20220388. doi:10.35541/cjd.20220388

References ［27］

［1］	Sun KY, Fan Y, Wang YX, et al. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta⁃analysis from 2000 to 2020［J］. Semin Arthritis Rheum, 2021,51（1）:175⁃191. doi: 10.1016/j.semarthrit.2020.11.009.
［2］	Cao H, Xia Q, Pan M, et al. Gottron papules and gottron sign with ulceration: a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis［J］. J Rheumatol, 2016,43（9）:1735⁃1742. doi: 10.3899/jrheum.160024.
［3］	Irie K, Matsumura N, Hoshi M, et al. Inverse Gottron′s papules in patients with dermatomyositis: an underrecognized but important sign for interstitial lung disease［J］. Int J Dermatol, 2021,60（2）:e62⁃e65. doi: 10.1111/ijd.15204.
［4］	Intapiboon P, Siripaitoon B. Erythematous auricular papules in the fatal cases of anti⁃MDA5 antibody⁃positive interstitial lung disease［J］. Respir Med Case Rep, 2020,31:101299. doi: 10.1016/j.rmcr.2020.101299.
［5］	Nishio M, Endo Y, Kosaka K, et al. Anti⁃aminoacyl⁃tRNA synthetases antibody positive overlap syndrome of systemic sclerosis and dermatomyositis associated with rapidly progressive interstitial lung disease［J］. J Dermatol, 2021,48（2）:e110⁃e111. doi: 10.1111/1346⁃8138.15692.
［6］	Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti⁃MDA5 antibody: Study of 121 cases［J］. Neurology, 2020,95（1）:e70⁃e78. doi: 10.1212/WNL.0000000000009727.
［7］	Li Y, Li Y, Wu J, et al. Predictors of poor outcome of anti⁃MDA5⁃associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis［J］. J Immunol Res, 2020,2020:2024869. doi: 10.1155/2020/2024869.
［8］	Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti⁃melanoma differentiation⁃associated gene 5 antibody［J］. Arthritis Care Res（Hoboken）, 2012,64（10）:1602⁃1610. doi: 10.1002/acr.21728.
［9］	Chen M, Zhao Q, Diao L, et al. Distribution of anti⁃melanoma differentiation associated gene 5（MDA5） IgG subclasses in MDA5+ dermatomyositis［J］. Rheumatology（Oxford）, 2021,61（1）:430⁃439. doi: 10.1093/rheumatology/keab268.
［10］	Xu A, Ye Y, Fu Q, et al. Prognostic values of anti⁃Ro52 antibodies in anti⁃MDA5⁃positive clinically amyopathic dermatomyositis associated with interstitial lung disease［J］. Rheumatology（Oxford）, 2021,60（7）:3343⁃3351. doi: 10.1093/rheumatology/keaa786.
［11］	Gono T, Masui K, Nishina N, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis⁃associated interstitial lung disease［J］. Arthritis Rheumatol, 2021,73（4）:677⁃686. doi: 10.1002/art.41566.
［12］	Lou Y, Zheng Y, Fan B, et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis⁃associated interstitial lung disease［J］. BMC Pulm Med, 2020,20（1）:196. doi: 10.1186/s12890⁃020⁃01226⁃3.
［13］	Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis［J］. Br J Dermatol, 2018,179（6）:1334⁃1341. doi: 10.1111/bjd. 17079.
［14］	Matsuda S, Kotani T, Ishida T, et al. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis⁃interstitial lung disease［J］. Rheumatology（Oxford）, 2020,59（2）:310⁃318. doi: 10.1093/rheumatology/kez301.
［15］	Borio G, Terracciano C, Buttafava F, et al. Skin rash and interstitial pneumonia can be a fatal combination: a rare case of anti⁃melanoma differentiation⁃associated gene 5（MDA5）⁃associated interstitial lung disease［J］. Eur J Case Rep Intern Med, 2021,8（10）:002860. doi: 10.12890/2021_002860.
［16］	Palawisuth S, Kantikosum K, Patiyasikunt M, et al. A bad sign: dermatomyositis with interstitial lung disease［J］. Am J Med, 2019,132（2）:182⁃186. doi: 10.1016/j.amjmed.2018.09.013.
［17］	Bai Z, Shen G, Dong L. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy［J］. Int J Rheum Dis, 2021,24（6）:815⁃827. doi: 10.1111/1756⁃185X.14128.
［18］	Shen YW, Zhang YM, Huang ZG, et al. Increased levels of soluble CD206 associated with rapidly progressive interstitial lung disease in patients with dermatomyositis［J］. Mediators Inflamm, 2020,2020:7948095. doi: 10.1155/2020/7948095.
［19］	Fujisawa T, Hozumi H, Yasui H, et al. Clinical significance of serum chitotriosidase level in anti⁃MDA5 antibody⁃positive dermatomyositis⁃associated interstitial lung disease［J］. J Rheumatol, 2019,46（8）:935⁃942. doi: 10.3899/jrheum.180825.
［20］	Gao Y, Zhao Q, Xie M, et al. Prognostic evaluation of serum osteopontin in patients with anti⁃MDA5 antibody⁃positive dermatomyositis associated interstitial lung disease［J］. Cytokine, 2020,135:155209. doi: 10.1016/j.cyto.2020.155209.
［21］	Peng QL, Zhang YM, Liang L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis［J］. Clin Exp Immunol, 2020,199（3）:314⁃325. doi: 10.1111/cei.13404.
［22］	Zhu D, Qiao J, Tang S, et al. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis［J］. Rheumatology（Oxford）, 2021,60（8）:3896⁃3903. doi: 10.1093/rheumatology/keaa819.
［23］	Wang C, Hou J, Lai J, et al. Correlation between CT score and KL⁃6: a severity assessing in juvenile dermatomyositis associated interstitial lung disease［J］. Can Respir J, 2023,2023:5607473. doi: 10.1155/2023/5607473.
［24］	Xu W, Wu W, Zhang D, et al. A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti⁃MDA5 positive dermatomyositis［J］. Sci Rep, 2021,11（1）:17070. doi: 10.1038/s41598⁃021⁃96292⁃w.
［25］	Xu W, Wu W, Zheng Y, et al. A Computed tomography radiomics⁃based prediction model on interstitial lung disease in anti⁃MDA5⁃positive dermatomyositis［J］. Front Med（Lausanne）, 2021,8:768052. doi: 10.3389/fmed.2021.768052.
［26］	Cao H, Liang J, Xu D, et al. Radiological characteristics of patients with anti⁃MDA5⁃antibody⁃positive dermatomyositis in（18）F⁃FDG PET/CT: a pilot study［J］. Front Med（Lausanne）, 2021,8:779272. doi: 10.3389/fmed.2021.779272.
［27］	Li J, Wei W, Xu W, et al. ［（68）Ga］Ga⁃FAPI⁃04 and ［（18）F］FDG PET/ CT in a patient with MDA5 dermatomyositis［J］. Eur J Nucl Med Mol Imaging, 2023. doi: 10.1007/s00259⁃023⁃06291⁃4.

[1]	Chen Zhu, Dong Liping, Xiao Fengli, . Research progress in atopic diseases from the perspective of metabolomics [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220366-e20220366.
[2]	Pan Ruoxin, Gu Duoduo, Zhang Yue, Li Min, Tao Meng, Xu Yang. Metabolomics in rosacea [J]. Chinese Journal of Dermatology, 2024, 57(2): 178-181.
[3]	Huang Xiaoyan, Xiao Yi, Jing Danrong, Chen Mingliang, Shen Minxue, . A survey on the prevalence and associated factors of arsenic poisoning-related skin lesions in an arsenic tailing area in Hunan Province, China [J]. Chinese Journal of Dermatology, 2023, 56(7): 636-641.
[4]	Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.
[5]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022 [J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.
[6]	Yang Ji, Xu Xinzhi, Li Ming. Early diagnosis of dermatomyositis and early recognition of visceral injury [J]. Chinese Journal of Dermatology, 2023, 56(2): 161-164.
[7]	Zhan Jinshan, Xuan Xiuyun, Cao Juanmei, Chen Fangqi, Huang Changzheng. Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220368-e20220368.
[8]	He Qing, Zhang Tao, Wang Xiuli, Gao Xinghua, Chen Hongduo, Liu Min, Qi Ruiqun. Biomarkers associated with malignant progression of actinic keratosis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220284-e20220284.
[9]	Zhang Shimin, Hu Yunyun, Zhao Xiaoqing, Du Lianjun, Cao Hua, Zheng Jie. Application of imaging techniques in diagnosis and severity assessment of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(7): 637-640.
[10]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[11]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.
[12]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[13]	Cao Hua, Zheng Jie . Evolution of diagnostic criteria for clinically amyopathic dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(11): 1008-1013.
[14]	Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases. Chinese Expert consensus on the diagnosis and treatment of adult dermatomyositis （2022） [J]. Chinese Journal of Dermatology, 2022, 55(11): 939-949.
[15]	Yang Ji, Xu Xinzhi, Li Ming. Pseudoangioedema: a new type of skin lesions of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(11): 1019-1020.

Evaluation of dermatomyositis complicated by interstitial lung disease based on skin lesions, serum biomarkers and radiological features

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［27］

Related Articles 15

Metrics

Comments

Recommended 10